ID: ALA26511

Max Phase: Preclinical

Molecular Formula: C32H29N3O3

Molecular Weight: 503.60

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCC(=O)c1ccc(C#CC(O)(c2ccc(C#N)cc2)c2cncn2C)c(-c2cccc(OC)c2)c1

Standard InChI:  InChI=1S/C32H29N3O3/c1-4-5-9-30(36)26-13-12-24(29(19-26)25-7-6-8-28(18-25)38-3)16-17-32(37,31-21-34-22-35(31)2)27-14-10-23(20-33)11-15-27/h6-8,10-15,18-19,21-22,37H,4-5,9H2,1-3H3

Standard InChI Key:  QMIGNVNXSVGBEL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 503.60

Molecular Weight (Monoisotopic): 503.2209

AlogP: 5.63

#Rotatable Bonds: 8

Polar Surface Area: 88.14

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.19

CX Basic pKa: 5.87

CX LogP: 5.49

CX LogD: 5.48

Aromatic Rings: 4

Heavy Atoms: 38

QED Weighted: 0.25

Np Likeness Score: -0.73

References

1. Lin NH, Wang L, Cohen J, Gu WZ, Frost D, Zhang H, Rosenberg S, Sham H..  (2003)  Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.,  13  (7): [PMID:12657267] [10.1016/s0960-894x(03)00122-7]

Source

Source(1):

• Scientific Literature